Plant flavone Chrysin as an emerging histone deacetylase inhibitor for prosperous epigenetic‐based anticancer therapy

Aberrations in epigenetic mechanisms provide a fertile platform for tumour initiation and progression. Thus, agents capable of modulating the epigenetic environment of neoplasms will be a valuable addition to the anticancer therapeutics. Flavones are emerging as befitting anticancer agents due to th...

Full description

Saved in:
Bibliographic Details
Published in:Phytotherapy research 2021-02, Vol.35 (2), p.823-834
Main Authors: Ganai, Shabir Ahmad, Sheikh, Farooq Ahmad, Baba, Zahoor Ahmad
Format: Article
Language:English
Subjects:
Anticancer properties
anticancer therapy
Antineoplastic Agents - pharmacology
Antineoplastic Agents - therapeutic use
Antioxidants
Antitumor agents
Breast cancer
Cancer
Cancer therapies
Cervix
Chemoresistance
Chrysin
Combinatorial analysis
Cytotoxicity
epidrug
Epigenesis, Genetic - drug effects
Epigenetics
Flavones
Flavones - chemistry
Flavonoids - chemistry
HDAC inhibitor
HDACs
Hepatocellular carcinoma
Histone deacetylase
Histone Deacetylase Inhibitors - pharmacology
Histone Deacetylase Inhibitors - therapeutic use
Histones
Humans
Melanoma
nano‐combinatorial approach
Neoplasms
Pathogenesis
Plants - chemistry
Reagents
Tumors
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Aberrations in epigenetic mechanisms provide a fertile platform for tumour initiation and progression. Thus, agents capable of modulating the epigenetic environment of neoplasms will be a valuable addition to the anticancer therapeutics. Flavones are emerging as befitting anticancer agents due to their inherent antioxidant activity and the ability to restrain epi‐targets namely histone deacetylases (HDACs). HDACs have broader implications in pathogenesis of various cancers. Chrysin, a flavone possessing the ability to inhibit HDACs could prove as a potential anticancer drug. Thus, in this article we focussed on Chrysin and its distinct antineoplastic effect against bellicose malignancies including lung, colorectal, cervical, gastric, melanoma, hepatocellular carcinoma and breast cancer. The underlying signalling cascades triggered by Chrysin for inducing cytotoxic effect in these cancer models are discussed. Importantly, approaches towards combinatorial treatments by Chrysin and commercial anticancer agents are taken into account. The downstream molecular mechanism aroused by combined therapy for abrogating onerous cancer chemoresistance is delineated as well. Moreover, the nano‐combinatorial approach involving co‐encapsulation of Chrysin with other herbal and non‐herbal agents for clinical excellence is elucidated.
ISSN:0951-418X
1099-1573
DOI:10.1002/ptr.6869